IsletRx (pancreatic insulin secreting islets)
/ Kadimastem
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 18, 2024
Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates
(GlobeNewswire)
- "Leading biotechnology company Pluri Inc...today announced it has signed a tech transfer and manufacturing agreement with Kadimastem Ltd...PluriCDMO will manufacture two cell therapy product candidates for Kadimastem: AstroRx, clinical grade human astrocytes (nervous system supporting cells) for the treatment of ALS for an upcoming U.S. Food and Drug Administration (FDA) Phase 2a study; and IsletRx, clinical grade pancreatic islet cells which produce and secrete insulin and glucagon in response to blood glucose levels, for the treatment of diabetes."
Licensing / partnership • Amyotrophic Lateral Sclerosis • CNS Disorders • Diabetes • Metabolic Disorders
1 to 1
Of
1
Go to page
1